Seliger Barbara, Schlaf Gerald
Martin Luther University Halle-Wittenberg, Institute of Medical Immunology, Magdeburger Strasse 2, 06112 Halle, Germany.
Semin Cancer Biol. 2007 Dec;17(6):444-50. doi: 10.1016/j.semcancer.2007.07.001. Epub 2007 Jul 13.
Tumors have developed different strategies to escape from immune cell recognition which include the downregulation or loss of the classical HLA class I antigens as well as aberrant expression of non-classical HLA antigens like HLA-G. Abnormalities in MHC class surface expression have also been described in renal cell carcinoma (RCC) and represent mechanisms to avoid elimination by immune effector cells. We here review the structure/polymorphism, mRNA and protein expression profile of HLA-G in RCC and corresponding normal kidney epithelium, its mode of regulation and its functional consequences on immune responses. A heterogeneous constitutive HLA-G mRNA and/or protein expression was found in both RCC lesions and RCC cell lines, whereas normal kidney epithelium totally lack HLA-G mRNA and protein expression. In comparison to other tumor entities, the frequency of HLA-G expression is relatively high in RCC. Since HLA-G expression is lost during cultivation of RCC cells, the tumor microenvironment and/or endothelium appear to be involved in the regulation of HLA-G expression in this disease. HLA-G expression could be transcriptionally upregulated in RCC by interferons, IL-10 and gangliosides. Silencing of HLA-G expression in RCC is often associated with methylation of the HLA-G promoter which could be reverted by the treatment with demethylating agents. Functional studies using natural killer cells, lymphokine activated killer cells as well as antigen-specific CD8+ cytotoxic T lymphocytes demonstrated that HLA-G expression prevents lysis of RCC cells by these different immune effector cells. In contrast, HLA-G-negative normal kidney cells as well as HLA-G-negative RCC cells were not recognized by NK and T cells. Thus, HLA-G represents one important immune escape mechanism of human RCC which has an impact on the design of T and NK cell-based immunotherapies in this disease.
肿瘤已发展出不同策略以逃避免疫细胞识别,其中包括经典的HLA I类抗原下调或缺失,以及非经典HLA抗原(如HLA - G)的异常表达。肾细胞癌(RCC)中也有MHC类表面表达异常的描述,这是避免被免疫效应细胞清除的机制。我们在此综述RCC及相应正常肾上皮中HLA - G的结构/多态性、mRNA和蛋白质表达谱、其调控模式及其对免疫反应的功能影响。在RCC病变和RCC细胞系中均发现了异质性的组成性HLA - G mRNA和/或蛋白质表达,而正常肾上皮完全缺乏HLA - G mRNA和蛋白质表达。与其他肿瘤实体相比,RCC中HLA - G表达的频率相对较高。由于RCC细胞培养过程中HLA - G表达会丧失,肿瘤微环境和/或内皮似乎参与了该疾病中HLA - G表达的调控。RCC中HLA - G表达可被干扰素、IL - 10和神经节苷脂转录上调。RCC中HLA - G表达的沉默通常与HLA - G启动子的甲基化有关,用去甲基化剂处理可使其逆转。使用自然杀伤细胞、淋巴因子激活的杀伤细胞以及抗原特异性CD8 + 细胞毒性T淋巴细胞进行的功能研究表明,HLA - G表达可防止这些不同免疫效应细胞对RCC细胞的裂解。相反,HLA - G阴性的正常肾细胞以及HLA - G阴性的RCC细胞不被NK和T细胞识别。因此,HLA - G是人类RCC的一种重要免疫逃逸机制,对该疾病基于T细胞和NK细胞的免疫治疗设计有影响。